THOMAS JEFFERSON UNIVERSITY HOSPITAL and GenomOncology are co-developing a multi-assay integrated cancer profiling system.
Jefferson officials said they expects to launch the system for testing acute myeloid leukemia in their molecular pathology laboratory this fall.
Combining karyotype analysis, fluorescence in situ hybridization and the evaluation of mutational status of molecular markers by next generation sequencing, can lead to improved strategies for risk stratification and targeted therapy.
Traditionally, the results of these disparate tests have been reported separately.
To improve this situation, GenomOncology is expanding its GO Clinical Workbench platform to allow both independent and cumulative analysis and reporting of these assays.
